{"database": "lobbying", "table": "lobbying_activities", "is_view": false, "human_description_en": "where filing_period = \"second_quarter\", filing_year = 2023 and issue_code = \"PHA\" sorted by filing_year descending", "rows": [[2957575, "7b178cfd-76ff-4ab0-bfa0-f3bee1a34931", "2T", "PARDES BIOSCIENCES, INC.", 401106493, "PARDES BIOSCIENCES, INC.", 2023, "second_quarter", "PHA", "Physician prescribing of covid antivirals", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE", null, 120000, 0, 1, "2023-04-12T10:26:43-04:00"], [2998027, "50a8b457-7284-48c9-a8b3-244cec6c6c49", "2T", "THORN RUN PARTNERS", 400534596, "HUMANITY FORWARD", 2023, "second_quarter", "PHA", "Issues and legislation related to reduction of prescription medication for Americans.", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", 40000, null, 0, 1, "2023-06-27T10:06:23-04:00"], [2998122, "e7af16b4-d06b-4230-bc30-05d781846aea", "Q2", "MCDERMOTT+ LLC", 401103287, "ALLIANCE FOR RURAL HOSPITAL ACCESS", 2023, "second_quarter", "PHA", "Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-06-29T13:33:07-04:00"], [2998483, "a3205bf6-0e40-485b-bd67-4cc4aa7b6c97", "Q2", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2023, "second_quarter", "PHA", "S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2023-07-04T11:49:42-04:00"], [2998857, "93f06a6f-4f89-4219-9538-90044c2a2108", "Q2", "EMERGENT STRATEGIES", 401104778, "GENBIOPRO, INC.", 2023, "second_quarter", "PHA", "FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS).", "HOUSE OF REPRESENTATIVES,SENATE", 35000, null, 0, 0, "2023-07-05T10:32:58-04:00"], [2999110, "da91088d-6cdc-4e5b-ba56-6d844aa70e14", "Q2", "RED+BLUE STRATEGIES", 400693064, "COHERUS BIOSCIENCES", 2023, "second_quarter", "PHA", "Issues related to drug shortages in the United States and the role biosimilars can play. Issues related to cancer care and developing both biosimilar and novel treatments to fight disease. Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-05T19:04:30-04:00"], [2999113, "d2c21b73-b3f1-415a-bdc2-e63cf8a56fbb", "Q2", "STONINGTON GLOBAL", 401105189, "SORRENTO THERAPEUTICS, INC.", 2023, "second_quarter", "PHA", "Promoting non-opioid pain management alternatives.", "Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, null, 0, 0, "2023-07-05T19:16:07-04:00"], [2999135, "1dcbc5ab-ac19-4621-ad46-7057ddea9c82", "Q2", "AMERICAN COLLEGE OF CLINICAL PHARMACY", 57258, "AMERICAN COLLEGE OF CLINICAL PHARMACY", 2023, "second_quarter", "PHA", "Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.", "HOUSE OF REPRESENTATIVES,SENATE", null, 144981, 0, 0, "2023-07-06T04:40:27-04:00"], [2999300, "09db606d-59fe-4cca-9856-be82ae11a84b", "Q2", "REPUBLIC CONSULTING, LLC", 401016871, "IQVIA", 2023, "second_quarter", "PHA", "Monitor Health Data Policy.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-06T11:42:46-04:00"], [2999333, "682920dd-ec16-481a-a2f1-4d5d7e768bf2", "Q2", "DAVE KOLBE CONSULTING", 401104329, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION", 2023, "second_quarter", "PHA", "H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-06T12:35:51-04:00"], [2999596, "23fb37e5-6f2a-4dfb-b000-cbefcb617ca0", "Q2", "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 401103605, "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 2023, "second_quarter", "PHA", "Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring", "HOUSE OF REPRESENTATIVES,SENATE", null, 50000, 0, 0, "2023-07-07T09:44:31-04:00"], [3000073, "16202ca1-673a-45f7-a121-066a84644085", "Q2", "4C COMMUNICATIONS, INC.", 323717, "HEALTHCARE LEADERSHIP COUNCIL", 2023, "second_quarter", "PHA", "Medicare Advantage", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2023-07-09T11:34:40-04:00"], [3000498, "68bf36ca-68a4-466e-8c98-ade3926de446", "Q2", "PENN AVENUE PARTNERS", 400918672, "ALKERMES, INC.", 2023, "second_quarter", "PHA", "Regulatory and legislative issues impacting Alkermes. Appropriations.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-10T15:36:48-04:00"], [3000617, "90329d10-e2b5-417b-8a6f-39de2804e2b8", "Q2", "PENN AVENUE PARTNERS", 400918672, "UNITEDHEALTH GROUP, INC.", 2023, "second_quarter", "PHA", "Pharmacy benefit related issues.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office", 90000, null, 0, 0, "2023-07-11T06:22:35-04:00"], [3000960, "3a710a7d-8fa8-493a-bc40-c32d7350eaaa", "Q2", "FROST BROWN TODD LLC", 283572, "DISPOSERX", 2023, "second_quarter", "PHA", "Support Act", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2023-07-11T13:16:16-04:00"], [3001048, "7730e925-a96a-460d-b855-4d0870c1b0af", "Q2", "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 26672, "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 2023, "second_quarter", "PHA", "H.R. 1613 Drug Price Transparency in Medicaid Act of 2023 H.R. 1770 The Equitable Community Access to Pharmacist Services Act H.R. 2880 Protecting Patients Against PBM Abuses Act H.R. 2816 The PBM Sunshine and Accountability Act H.R. 3561 The Patient Act S. 113 Prescription Pricing for the People Act S. 127 Pharmacy Benefit Manager Transparency Act S. 1038 Drug Price Transparency in Medicaid Act of 2023 S. 1339 Pharmacy Benefit Manager Reform Act S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act S. 2052 Protect Patient Access to Pharmacies Act", "HOUSE OF REPRESENTATIVES,SENATE", null, 350000, 0, 0, "2023-07-11T15:13:29-04:00"], [3001166, "187335aa-af99-4a4b-88c4-548a9004493d", "Q2", "MR. H.R. BERT PENA", 400323519, "MARGO RX LLC(DBA RICHARD'S PHARMACY)", 2023, "second_quarter", "PHA", "PBM AND DRUG PRICES", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES", null, null, 0, 0, "2023-07-11T16:47:20-04:00"], [3001232, "f376ed09-b536-4cbe-968c-8642a1596970", "Q2", "HOLLAND & KNIGHT LLP", 18466, "VIATRIS INC", 2023, "second_quarter", "PHA", "Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues, E-labeling; Inflation Reduction Act Implementation, Improving Generic Drug Access, PEPFAR.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-12T07:45:28-04:00"], [3001307, "0838c757-1292-4775-ad38-9868578bb73b", "Q2", "GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS)", 400270236, "GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS)", 2023, "second_quarter", "PHA", "Monitoring PBM discussions (focused on Medicaid)", "HOUSE OF REPRESENTATIVES,SENATE", null, 8000, 0, 0, "2023-07-12T10:32:48-04:00"], [3001363, "7cba4ccc-1b9c-4c89-99c7-2c6e1152a936", "Q2", "LUNGREN LOPINA LLC", 401103314, "AMPAC FINE CHEMICALS", 2023, "second_quarter", "PHA", "Fair treatment for US based pharmaceutical ingredients", "Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2023-07-12T11:59:31-04:00"], [3001496, "4b5df1ae-9188-4aec-bbdb-0b1f1bb36521", "Q2", "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 27478, "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 2023, "second_quarter", "PHA", "H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 382, the Pandemic is Over Act; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542, the Delinking Revenue from Unfair Gouging Act; Draft legislation, To amend the Public Health Service Act to make updates to the Vaccine Injury Compensation Program; Draft legislation, To amend the Internal Revenue Code of 1986 to provide authority to add additional vaccines to the list of taxable vaccines.", "Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 380000, 0, 0, "2023-07-12T13:49:53-04:00"], [3001698, "1093d563-d57f-4677-b3e0-cadc59f6d4a5", "Q2", "COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE", 11003, "COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE", 2023, "second_quarter", "PHA", "CCAGW Urges Senate Health, Education, Labor and Pensions Committee to Oppose S. 1339", "SENATE", null, 1100000, 0, 0, "2023-07-12T15:12:10-04:00"], [3002289, "53672623-3a00-4084-8594-cf0181aa8ee1", "Q2", "THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH", 401104060, "THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH", 2023, "second_quarter", "PHA", "Increasing prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining prior authorization processes. S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", null, 60000, 0, 0, "2023-07-13T10:45:44-04:00"], [3003232, "52ec1be5-7354-40e0-86fa-5d0ae42f3ca1", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "ABBOTT LABORATORIES", 2023, "second_quarter", "PHA", "Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770, the Equitable Community Access to Pharmacist Services Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-13T16:44:46-04:00"], [3003306, "650c7abe-e655-4b76-8484-30231b749509", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION)", 2023, "second_quarter", "PHA", "Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770, The Equitable Community Access to Pharmacist Services Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-13T17:07:33-04:00"], [3004423, "98782e6a-8808-4d81-a9ad-00e511c0d67e", "Q2", "MARSHALL & POPP, LLC", 401105121, "AMGEN USA INC.", 2023, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-14T15:47:53-04:00"], [3004477, "5ec12dbc-ae37-460b-86d6-5ce5efaba815", "Q2", "MARSHALL & POPP, LLC", 401105121, "GENENTECH, INC.", 2023, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act,. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-14T16:05:24-04:00"], [3004496, "32eaa44d-86e3-4041-aca5-1feeec8676d4", "Q2", "MARSHALL & POPP, LLC", 401105121, "PFIZER, INC.", 2023, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-14T16:12:24-04:00"], [3004505, "386b2b59-e53d-4968-a10b-534bd5aa1224", "Q2", "MARSHALL & POPP, LLC", 401105121, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2023, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2023-07-14T16:14:46-04:00"], [3004512, "70c2d79f-107a-443d-84ca-1b215c95dfff", "Q2", "MARSHALL & POPP, LLC", 401105121, "SANOFI U.S. SERVICES, INC.", 2023, "second_quarter", "PHA", "Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, and H.R. 2679, the PBM Accountability Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-14T16:17:25-04:00"], [3004592, "e36e599d-4cd3-44bb-bf88-09463c21db01", "Q2", "HOGAN LOVELLS US LLP", 18422, "ALVOGEN, PHARMA US, INC.", 2023, "second_quarter", "PHA", "Issues related to COVID-19", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2023-07-14T16:39:21-04:00"], [3004680, "13bccf1c-26f8-417a-a055-fa39cca3e397", "Q2", "ASCENSION HEALTH ALLIANCE D/B/A ASCENSION", 401105339, "ASCENSION HEALTH ALLIANCE D/B/A ASCENSION", 2023, "second_quarter", "PHA", "340B Program; Issues related to affordable prescription drugs;H.R. 1770, Equitable Access to Pharmacy Services Act; H.R. 3008, the Drug Shortage Prevention Act; H.R. 3810, the Drug Origin Transparency Act; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act; issues related to preventing and mitigating drug shortages;", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 300000, 0, 0, "2023-07-14T17:25:50-04:00"], [3005155, "d9a329de-4999-4197-99bb-24f6aa91e968", "Q2", "INDEPENDENT PHARMACY COOPERATIVE", 313098, "INDEPENDENT PHARMACY COOPERATIVE", 2023, "second_quarter", "PHA", "IPC supports S.127 Pharmacy Benefit Manager Transparency Act of 2023. IPC supports S.113 Prescription Pricing for the People Act of 2023. IPC supports H.R. 1770 Equitable Community Access to Pharmacists Services Act of 2023. IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC supports H.R. 1613 Drug Price Transparency in Medicaid Act of 2023. IPC supports S. 1038 Drug Price Transparency in Medicaid Act of 2023 IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports H.R. 3561 Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act of 2023 IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act", "Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE", null, 40000, 0, 0, "2023-07-15T15:26:49-04:00"], [3005306, "7c2137b1-a0b0-4891-903c-41fa476c8e07", "Q2", "FORBES-TATE", 400976792, "INDEPENDENT PHARMACY COOPERATIVE", 2023, "second_quarter", "PHA", "Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-15T18:14:43-04:00"], [3005426, "d1ca60a5-ace2-46a9-bd4e-a3b0bf290eed", "Q2", "CORNERSTONE GOVERNMENT AFFAIRS, INC.", 75557, "CHILDREN'S NATIONAL MEDICAL CENTER", 2023, "second_quarter", "PHA", "Health-related issues including reimbursement, research, public-health & clinical care.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 50000, null, 0, 0, "2023-07-15T22:49:17-04:00"], [3005542, "94323d03-5f40-4def-959a-1777b50eec88", "Q2", "FORBES-TATE", 400976792, "PHRMA", 2023, "second_quarter", "PHA", "Issues pertaining to prescription drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2023-07-16T10:45:24-04:00"], [3005726, "40e0438d-caea-410c-b931-a58bc358b4c6", "Q2", "FORBES-TATE", 400976792, "CALIFORNIA LIFE SCIENCES ASSOCIATION", 2023, "second_quarter", "PHA", "Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2023-07-16T12:38:22-04:00"], [3005821, "a77f3f72-86cf-4895-b226-0202000dc1a0", "Q2", "CORNERSTONE GOVERNMENT AFFAIRS, INC.", 75557, "MICHIGAN HEALTH & HOSPITAL ASSOCIATION", 2023, "second_quarter", "PHA", "Advised on FY 24 Labor-Health and Human Services-Education appropriations; Medicare reimbursement; Medicaid coverage; health care workforce issues; Rural Emergency Hospital designation; and cancer drug shortages. Engaged with Michigan congressional delegation offices.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-16T14:44:07-04:00"], [3005839, "57477cbd-1c6d-438d-98e4-544a0a70d7a5", "Q2", "PORT SIDE STRATEGIES, LLC", 401105394, "SOCIAL SECURITY WORKS", 2023, "second_quarter", "PHA", "Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-16T14:58:00-04:00"], [3005841, "b3860da1-d311-4999-a41f-76a8976b954a", "Q2", "PORT SIDE STRATEGIES, LLC", 401105394, "NEW VENTURE FUND", 2023, "second_quarter", "PHA", "Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. H.R.485 - Protecting Health Care for All Patients Act of 2023 - opposed. S. 1264 - SMART Prices Act - in support. S. 1323 - End Price Gouging for Medications Act - in support. S. 2157 - A bill to repeal prescription drug price control provisions of the Inflation Reduction Act - opposed. S. 1339 - Pharmacy Benefit Manager Reform Act - in support. S. 1214 - RARE Act - in support. S. 1114 - Expanding Access to Low-Cost Generics Act of 2023 - in support. S.1067 - Ensuring Timely Access to Generics Act of 2023 - in support.", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2023-07-16T15:00:08-04:00"], [3005850, "fbc6f89e-3ed4-4a69-8894-7574069bc897", "Q2", "PORT SIDE STRATEGIES, LLC", 401105394, "CENTER FOR HEALTH AND DEMOCRACY", 2023, "second_quarter", "PHA", "Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. S. 1323 - End Price Gouging for Medications Act - in support. S. 1339 - Pharmacy Benefit Manager Reform Act - in support.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2023-07-16T15:03:05-04:00"], [3006746, "31ccf3cf-9283-4f87-bb19-192beb4862f1", "Q2", "RICCHETTI INCORPORATED", 62778, "EISAI, INC.", 2023, "second_quarter", "PHA", "Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-17T11:40:10-04:00"], [3006775, "3b2ae974-ff55-44ca-bea3-0d5d63eaff60", "Q2", "RICCHETTI INCORPORATED", 62778, "HORIZON THERAPEUTICS USA INC", 2023, "second_quarter", "PHA", "Issues related to pharmaceutical industry, generally; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2023-07-17T11:45:18-04:00"], [3006801, "0de0ec95-27b3-407e-a4d3-551d9ef2021d", "Q2", "RICCHETTI INCORPORATED", 62778, "IPSEN BIOPHARMACEUTICALS, INC.", 2023, "second_quarter", "PHA", "Issues related to pharmaceutical industry, generally Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-17T11:50:01-04:00"], [3006815, "9a6045ac-fac7-4d81-99aa-70b25598f8f6", "Q2", "RICCHETTI INCORPORATED", 62778, "NEUROCRINE BIOSCIENCES, INC.", 2023, "second_quarter", "PHA", "Issues related to pharmaceutical industry, generally", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-17T11:52:06-04:00"], [3006973, "cf662790-b8ab-45e3-ae2d-d5d3842e55f9", "Q2", "KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS)", 401105192, "CVS HEALTH", 2023, "second_quarter", "PHA", "Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-17T12:56:34-04:00"], [3007129, "d7c40bc3-2d88-45ac-9bc6-bfebc569ad6a", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2023, "second_quarter", "PHA", "General issues related to over-the-counter pharmaceutical supply chain.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-17T13:47:14-04:00"], [3007297, "bb7ed993-72a4-4a78-9139-22f1247988aa", "Q2", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CVS HEALTH", 2023, "second_quarter", "PHA", "Issues related to drug pricing transparency and COVID-19 testing, vaccination and treatment. H.R. 1770, the Equitable Community Access to Pharmacist Services Act.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2023-07-17T14:25:42-04:00"], [3007667, "a820664a-2958-4f3d-9b17-759e35c562c4", "Q2", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.)", 2023, "second_quarter", "PHA", "Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 501 Halt, Block, and Suspend Suspicious Orders HR 467 HALT Fentanyl Act HR 1770 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA)", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 80000, null, 0, 0, "2023-07-17T15:25:14-04:00"], [3007707, "ba87825b-c6a2-46c0-97c8-91306a9a93aa", "Q2", "WAXMAN STRATEGIES", 401103693, "340B HEALTH", 2023, "second_quarter", "PHA", "Issues affecting the 340B drug pricing program; Appropriations for 340B program.", "HOUSE OF REPRESENTATIVES,SENATE", 45000, null, 0, 0, "2023-07-17T15:34:29-04:00"], [3008233, "908e37a5-d53b-4e94-b77b-9e464def28d2", "Q2", "STUMPTOWN STRATEGIES", 401106433, "PRIME THERAPEUTICS", 2023, "second_quarter", "PHA", "Introduction to Prime to new Members of the 118th Congress Monitoring PBM Legislation (bill numbers not yet finalized)", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-17T18:14:21-04:00"], [3008401, "0b456173-b78f-4628-a9eb-c1ecb7c0f937", "Q2", "PANNONE LOPES DEVEREAUX & O'GARA LLC", 401105501, "AMGEN", 2023, "second_quarter", "PHA", "Prescription drug pricing.", null, 9000, null, 0, 0, "2023-07-17T19:31:38-04:00"], [3008932, "2aeb659f-d305-4a4f-9143-123e175c6e33", "Q2", "THE CONSILIO GROUP", 400374717, "PARATEK PHARMACEUTICALS", 2023, "second_quarter", "PHA", "Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use", "Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office", 36000, null, 0, 0, "2023-07-18T09:26:18-04:00"], [3009109, "36288351-bfcc-44ca-92a4-1b16d9efc17c", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "AIM IMMUNOTECH INC.", 2023, "second_quarter", "PHA", "Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-18T09:50:21-04:00"], [3009245, "17304f11-a333-4519-b9e9-74e57c94f487", "Q2", "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 29403, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2023, "second_quarter", "PHA", "OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act -- not yet introduced. FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 171093, null, 0, 0, "2023-07-18T10:17:34-04:00"], [3009440, "61d4f7d6-e612-410d-a2a7-9a3258b99a3c", "Q2", "WATKINS & EAGER PLLC", 401104403, "ZYNERBA PHARMACEUTICALS, INC.", 2023, "second_quarter", "PHA", "Encourage Members to act favorably on matters of importance to Zynerba at their direction; Trial for medication that could help individuals with Fragile X Syndrome.", "HOUSE OF REPRESENTATIVES,SENATE", 45000, null, 0, 0, "2023-07-18T11:00:12-04:00"], [3009453, "969ee106-f487-4914-94bd-8c06ab442b92", "Q2", "POWERS PYLES SUTTER & VERVILLE, P.C.", 32008, "NATIONAL ASSOCIATION OF SPECIALTY PHARMACY", 2023, "second_quarter", "PHA", "Pharmacy market competition.", "Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE", 120000, null, 0, 0, "2023-07-18T11:03:25-04:00"], [3009652, "816ed45f-fff3-4cf9-bd70-27b5725da4f3", "2A", "HEALTHSPERIEN", 401103150, "EXACT CARE PHARMACY", 2023, "second_quarter", "PHA", "Advocate for codifying definition for long-term care pharmacy. (S. 1574) Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2023-07-18T11:27:16-04:00"], [3010107, "8c138b03-ef60-43bf-98ce-96b3c5932b22", "Q2", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "ACER THERAPEUTICS", 2023, "second_quarter", "PHA", "COVID-19 therapeutics and Medical Countermeasures, Rare Disease, and Re-purposed drugs; Defense Appropriations for MCM Development", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-18T12:52:00-04:00"], [3010145, "f9651e0f-e5eb-41c4-9bd7-0d66b9b58554", "2T", "ALPINE GROUP PARTNERS, LLC.", 1171, "MINDBLOOM, INC.", 2023, "second_quarter", "PHA", "Telehealth legislation and regulation Mental health policy", "HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 1, "2023-07-18T13:00:13-04:00"], [3010149, "4e731395-b33f-443c-88c8-3166168d89b1", "Q2", "AMERICAN PHARMACISTS ASSOCIATION", 3071, "AMERICAN PHARMACISTS ASSOCIATION", 2023, "second_quarter", "PHA", "Provider status", "HOUSE OF REPRESENTATIVES,SENATE", null, 35000, 0, 0, "2023-07-18T13:00:28-04:00"], [3010167, "34e57209-0d03-4007-9d59-3077e7151754", "Q2", "340B HEALTH", 316434, "340B HEALTH", 2023, "second_quarter", "PHA", "The 340B Drug Pricing Program; The Protect 340B Act; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bill. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023", "Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 360515, 0, 0, "2023-07-18T13:06:22-04:00"], [3010168, "db5b1850-f0d0-4efe-9642-c597dec26fe4", "Q2", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "TONIX PHARMACEUTICALS HOLDING CORP.", 2023, "second_quarter", "PHA", "LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2023-07-18T13:06:28-04:00"], [3010188, "fbec5cf1-1278-4666-9c22-25b1187a3a1e", "Q2", "BURRELL INTERNATIONAL GROUP LLC", 401103483, "SHIONOGI INC.", 2023, "second_quarter", "PHA", "Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-18T13:08:03-04:00"], [3010227, "ba0a690a-c6b3-4fe6-9bcf-eb048203c8ea", "Q2", "LINCOLN PARK GROUP L.L.C.", 401104374, "CANADIAN INTERNATIONAL PHARMACY ASSOCIATION", 2023, "second_quarter", "PHA", "Issues related to importation of medicines for personal use.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2023-07-18T13:14:42-04:00"], [3010289, "53a770de-a6fd-453a-843e-a740478d3381", "Q2", "DA VINCI GROUP", 11548, "BOESEN & SNOW, LLC", 2023, "second_quarter", "PHA", "Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2023-07-18T13:23:41-04:00"], [3010320, "a594db2f-d9fd-463e-ad4f-7f77f38b21a0", "Q2", "HANCE SCARBOROUGH", 17443, "ALLIANCE FOR PHARMACY COMPOUNDING", 2023, "second_quarter", "PHA", "Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2024 Appropriations HR167, the Patient Access to Urgent Use Compounded Medication Act", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-18T13:34:02-04:00"], [3010360, "246f2254-7800-426f-9309-7ba6bb6aff8d", "Q2", "SQUIRE PATTON BOGGS", 30906, "SK HYNIX AMERICA, INC.", 2023, "second_quarter", "PHA", "Monitor proposals and issues related to biopharmaceuticals.", "HOUSE OF REPRESENTATIVES,SENATE", 110000, null, 0, 0, "2023-07-18T13:42:44-04:00"], [3010668, "38721f94-9c39-4b68-a6a1-17ed4dff9038", "Q2", "MEHLMAN CONSULTING, INC.", 284950, "THE CAMPAIGN FOR SUSTAINABLE RX PRICING", 2023, "second_quarter", "PHA", "Prescription drug pricing issues. Pricing of Covid 19 vaccines. H.R. 485 - the Protecting Health Care for All Patients Act. S. 775 - Increasing Transparency in Generic Drug Applications Act. S. 1214 - Retaining Access and Restoring Exclusivity Act. S. 1067 - Ensuring Timely Access to Generics Act. S. 935 - Fair Accountability and Innovative Research Drug Pricing Act of 2023.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-18T14:24:02-04:00"], [3010819, "4f067cc8-96fd-4dde-86ad-ccbc186f25a2", "Q2", "E3 STRATEGIC CONSULTING GROUP", 401104104, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION", 2023, "second_quarter", "PHA", "Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act\").", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-18T14:41:44-04:00"], [3010974, "075c4aac-89a5-4b3a-9076-f4fecc7513a8", "Q2", "HB STRATEGIES", 401104718, "BAYER U.S. LLC", 2023, "second_quarter", "PHA", "Provide lobbying support of key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare and agricultural industries generally and Bayer specifically.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-18T15:01:40-04:00"], [3011089, "c4288008-e13a-4f59-83c7-8d42de0d8fa7", "Q2", "WINNING STRATEGIES WASHINGTON", 50796, "KALEO", 2023, "second_quarter", "PHA", "Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2023-07-18T15:13:15-04:00"], [3011220, "955dec8e-f38e-4b1d-8cd5-658f399dd4fe", "Q2", "DESIMONE CONSULTING, LLC", 400931695, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)", 2023, "second_quarter", "PHA", "Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2023-07-18T15:26:12-04:00"], [3011313, "41a9886f-9576-4cf0-97e1-41b4bc6d1b28", "Q2", "TRUSYNERGY", 401107715, "BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.)", 2023, "second_quarter", "PHA", "Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2023-07-18T15:35:51-04:00"], [3011387, "4f8ff701-a57f-4f10-8498-a26d91fa59eb", "Q2", "DENTONS US LLP", 36105, "PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA", 2023, "second_quarter", "PHA", "Federal issues impacting workforce and innovation in the pharmaceutical industry.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-18T15:47:30-04:00"], [3011515, "784dfdf7-297c-4a63-8579-e8bb5c7134ad", "Q2", "HANCE SCARBOROUGH", 17443, "BOEHRINGER INGELHEIM USA CORPORATION", 2023, "second_quarter", "PHA", "Provide ongoing animal health policy monitoring, assessment, and research support. Telemedicine/telehealth legislation.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-18T16:16:23-04:00"], [3011711, "d5f4ba8f-31ee-491b-aa4f-96bdc2c0df9b", "Q2", "HANCE SCARBOROUGH", 17443, "PHRMA", 2023, "second_quarter", "PHA", "Patent reform regarding pharmaceutical research & products.", "SENATE", null, null, 0, 0, "2023-07-18T16:57:24-04:00"], [3011872, "5c098719-7de8-4e69-8a94-921269cb3886", "Q2", "ARENTFOX SCHIFF LLP", 4208, "AMERICAN PHARMACY COOPERATIVE, INC.", 2023, "second_quarter", "PHA", "Prescription drug pricing generally", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-18T17:36:45-04:00"], [3011993, "7fc25e87-49d8-4b0c-8fe4-edb6498a65e5", "Q2", "BLUE SHIELD OF CALIFORNIA", 6518, "BLUE SHIELD OF CALIFORNIA", 2023, "second_quarter", "PHA", "Matters related to pharmacy benefit manager reform.", "HOUSE OF REPRESENTATIVES,SENATE", null, 110000, 0, 0, "2023-07-18T18:21:56-04:00"], [3012004, "bcd3ded5-9476-4ccb-ad34-5003103db7de", "Q2", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "WALGREEN CO.", 2023, "second_quarter", "PHA", "Pharmacist provider status Issues related to drug pricing Implementation of the Inflation Reduction Act of 2022 INFORM Act Issues related to access and distribution of pharmaceutical products", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-18T18:30:42-04:00"], [3012309, "c75126c5-2e91-4581-9b3c-c51ba8326277", "Q2", "CAPITOL COUNSEL LLC", 313715, "EMD SERONO, INC.", 2023, "second_quarter", "PHA", "Issues regarding the availability and pricing of prescription drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-18T21:15:29-04:00"], [3012387, "ade8a9ac-ade3-4aa2-a9c1-c2d9bc373b63", "Q2", "PRIME POLICY GROUP", 400532589, "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 2023, "second_quarter", "PHA", "HR 1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; PREP Act authorities", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", 80000, null, 0, 0, "2023-07-18T21:47:24-04:00"], [3012635, "e1bca7cf-0aa5-4a52-8899-abeb5c25ebee", "2A", "PRIME POLICY GROUP", 400532589, "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 2023, "second_quarter", "PHA", "HR 1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; PREP Act authorities", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", 80000, null, 0, 0, "2023-07-18T23:03:33-04:00"], [3012958, "dc0f7546-b1c6-4009-8ebd-605493305cb7", "Q2", "VAN SCOYOC ASSOCIATES", 39837, "ZEBRA TECHNOLOGIES CORP.", 2023, "second_quarter", "PHA", "H.R.2670, National Defense Authorization Act for Fiscal Year 2024, Temperature monitoring technology Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2024, Temperature monitoring related issues", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-19T06:54:10-04:00"], [3013057, "d4a84497-d5c6-4c95-9750-c4cdb88375f5", "Q2", "ARNOLD & PORTER KAYE SCHOLER LLP", 4301, "NOVO NORDISK, INC.", 2023, "second_quarter", "PHA", "Issues related to pharmacy benefit managers and the 340B Program.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-19T07:59:48-04:00"], [3013441, "cece17f6-aebe-449f-befd-6bcb8c406986", "Q2", "ELI LILLY AND COMPANY", 13392, "ELI LILLY AND COMPANY", 2023, "second_quarter", "PHA", "Hospital discounts; 340B program", "HOUSE OF REPRESENTATIVES,SENATE", null, 1585000, 0, 0, "2023-07-19T09:28:21-04:00"], [3013484, "40c60cbb-46e9-430e-b5be-0327eef5f1cf", "Q2", "KING & SPALDING LLP", 21632, "SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)", 2023, "second_quarter", "PHA", "Advocacy on low income subsidy benefits", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2023-07-19T09:39:16-04:00"], [3013600, "89e516fb-73a1-4962-9dd6-79730b1981b1", "Q2", "CARD & ASSOCIATES, LLC", 84217, "AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY)", 2023, "second_quarter", "PHA", "Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2024 Appropriations Support access to telehealth Monitor and engage on EU digital regulatory policies", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-19T10:04:38-04:00"], [3013677, "f9e61ef5-ab9a-4915-8a2e-b3716a095aa4", "Q2", "THE ALS ASSOCIATION", 401104947, "THE ALS ASSOCIATION", 2023, "second_quarter", "PHA", "Promising Pathways Act (S.1906) - Discussion around a provisional approval path for drugs and biological interventions that meet unmet needs of rare diseases like ALS.", "HOUSE OF REPRESENTATIVES,SENATE", null, 25000, 0, 0, "2023-07-19T10:13:29-04:00"], [3013846, "ef200c5f-3ba4-48b6-aae6-c343ba7e2df4", "Q2", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "TIDELANDS HEALTH", 2023, "second_quarter", "PHA", "Issues related to the 340B Drug Pricing Program", "SENATE", 50000, null, 0, 0, "2023-07-19T10:33:53-04:00"], [3013864, "a0365158-ccca-4fbb-9edc-012cf1b8eb26", "Q2", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "HEMOPHILIA OF GEORGIA", 2023, "second_quarter", "PHA", "340B Drug Pricing Program, patient co-pays legislation (H.R. 830)", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2023-07-19T10:35:10-04:00"], [3013986, "2fa248be-9bf2-4ed4-8c7f-e170c4b0df5d", "Q2", "BROWN & FORTUNATO, P.C.", 401104878, "PROMPTCARE COMPANIES, INC.", 2023, "second_quarter", "PHA", "Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators.", "Centers For Medicare and Medicaid Services (CMS)", 10000, null, 0, 0, "2023-07-19T10:47:30-04:00"], [3013995, "2516e0eb-4ef2-4393-9185-024657e6ace9", "Q2", "BLUE CROSS BLUE SHIELD OF MICHIGAN", 46676, "BLUE CROSS BLUE SHIELD OF MICHIGAN", 2023, "second_quarter", "PHA", "Insulin Out of Pocket Charges; Finance PBNM Framework Proposals; S. 150 - Affordable Prescriptions for Patients Act of 2023 bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. John Cornyn (R-TX) S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services or prescription drugs, and for other purposes. Sponsor: Sen. Maria Cantwell (D-WA) S. 1067 - Ensuring Timely Access to Generics Act of 2023 o amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S. 1114 - Expanding Access to Low-Cost Generics Act of 2023 o amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 1269 - INSULIN Act of 2023 o reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH] S. 1339 - Pharmacy Benefit Manager Reform Act o provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health nsurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT]", "HOUSE OF REPRESENTATIVES,SENATE", null, 269075, 0, 0, "2023-07-19T10:47:49-04:00"], [3014388, "16b858f6-4220-44c7-98a6-9f74a4877546", "Q2", "AMERICAN VETERINARY MEDICAL ASSOCIATION", 3630, "AMERICAN VETERINARY MEDICAL ASSOCIATION", 2023, "second_quarter", "PHA", "H.R. 1418/ S. 1844 Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization H.R. 1839/S. 993 Combatting Illicit Xylazine Act Review of Food and Drug Administrations Final Guidance for industry #256: Compounding Animal Drugs from Bulk Drug Substances- H.R. 1683 Generic Animal Drug Advancement Act, all provisions", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE", null, 330000, 0, 0, "2023-07-19T11:17:12-04:00"], [3014673, "524765e7-fb25-4e2f-b15d-cf63a82e9d8c", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "FERA PHARMACEUTICALS, LLC", 2023, "second_quarter", "PHA", "Strategy development and implementation of federal government relations initiatives relating to phospholine iodide issues with the Food and Drug Administration and Centers for Medicare and Medicaid Services.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2023-07-19T11:37:56-04:00"], [3014926, "5e48f4cd-493f-4f73-b620-868377f4dd46", "Q2", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "GENERIC ANIMAL DRUG ALLIANCE", 2023, "second_quarter", "PHA", "Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-19T12:04:46-04:00"], [3015144, "4ea57e6f-15cf-4e8f-88ec-31d86730b1af", "Q2", "NATIONAL RIGHT TO LIFE COMMITTEE", 28481, "NATIONAL RIGHT LIFE COMMITTEE", 2023, "second_quarter", "PHA", "Contacts in support of proposed rule, \"Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation,\" 88 FR 12875 (March 1, 2023), (RIN): 1117-AB40, Docket ID DEA-407 due to impact of assisted suicide drugs. Contacts regarding vending machine dispensing of chemical abortion drugs.", "Drug Enforcement Administration (DEA),SENATE", null, 80000, 0, 0, "2023-07-19T12:25:17-04:00"], [3015164, "ba8694da-4d69-49e9-b422-853fec910351", "Q2", "BLUECROSS BLUESHIELD OF TENNESSEE", 6440, "BLUECROSS BLUESHIELD OF TENNESSEE", 2023, "second_quarter", "PHA", "Insulin Act; Insulin Out of Pocket Charges; Pharmacy Benefit Managers; Delinking PBM language S 954 - Affordable Insulin Now Act A bill to provide for appropriate cost-sharing for insulin products covered under private health plans and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. S. 1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage S.127 - PBM Transparency Act of 2023 To prevent unfair and deceptive acts or practices and the dissemination of false information related to PBM services for Rx drugs, etc.", "HOUSE OF REPRESENTATIVES,SENATE", null, 150000, 0, 0, "2023-07-19T12:28:49-04:00"], [3015378, "db79759c-915f-4a3c-a670-b7bcf68f9431", "Q2", "WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH", 401107274, "WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH", 2023, "second_quarter", "PHA", "any bills or provisions related to the 340b drug discount program", "HOUSE OF REPRESENTATIVES", null, 30589, 0, 0, "2023-07-19T12:50:17-04:00"], [3015412, "ddd7cd43-5a1d-44fa-b5fd-3e6377da1056", "Q2", "FAEGRE DRINKER BIDDLE & REATH LLP", 12631, "NATIONAL ASSOCIATION OF BOARDS OF PHARMACY", 2023, "second_quarter", "PHA", "Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth.", "Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE", 30000, null, 0, 0, "2023-07-19T12:53:01-04:00"]], "truncated": false, "filtered_table_rows_count": 284, "expanded_columns": [], "expandable_columns": [[{"column": "filing_uuid", "other_table": "lobbying_filings_raw", "other_column": "filing_uuid"}, "registrant_name"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, filing_uuid, filing_type, registrant_name, registrant_id, client_name, filing_year, filing_period, issue_code, specific_issues, government_entities, income_amount, expense_amount, is_no_activity, is_termination, received_date from lobbying_activities where \"filing_period\" = :p0 and \"filing_year\" = :p1 and \"issue_code\" = :p2 order by filing_year desc limit 101", "params": {"p0": "second_quarter", "p1": "2023", "p2": "PHA"}}, "facet_results": {"issue_code": {"name": "issue_code", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023&issue_code=PHA", "results": [{"value": "PHA", "label": "PHA", "count": 284, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023", "selected": true}], "truncated": false}, "filing_year": {"name": "filing_year", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023&issue_code=PHA", "results": [{"value": 2023, "label": 2023, "count": 284, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&issue_code=PHA", "selected": true}], "truncated": false}, "filing_period": {"name": "filing_period", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023&issue_code=PHA", "results": [{"value": "second_quarter", "label": "second_quarter", "count": 284, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_year=2023&issue_code=PHA", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "filing_type", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023&issue_code=PHA&_facet=filing_type"}, {"name": "income_amount", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023&issue_code=PHA&_facet=income_amount"}, {"name": "is_termination", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023&issue_code=PHA&_facet=is_termination"}, {"name": "received_date", "type": "date", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023&issue_code=PHA&_facet_date=received_date"}], "next": "2023,3015412", "next_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=second_quarter&filing_year=2023&issue_code=PHA&_next=2023%2C3015412&_sort_desc=filing_year", "private": false, "allow_execute_sql": true, "query_ms": 2081.7156169796363, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}